Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2008-03-18
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S113000
Reexamination Certificate
active
11077188
ABSTRACT:
Described herein are compounds that are useful as protein kinase inhibitors having the formula:wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
REFERENCES:
patent: WO 99/28315 (1999-06-01), None
patent: WO 01/56993 (2001-08-01), None
patent: WO 01/57022 (2001-08-01), None
patent: WO 02/064586 (2002-08-01), None
patent: WO 02/079193 (2002-10-01), None
Hoshino et al., “Constitutive activation of the 41-/43-KDa mitogen-activated protein kinase signaling pathway in human tumors,” Oncogene, 18:813-22 (1999).
Kortylewski et al., “Mitogen-activated protein kinases control p27/Kip1 expression and growth of human melanoma cells,” Biochemical Journal, 357(Pt 1):297-303 (2001).
Putz et al., “Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines,” Cancer Research, 59(1):227-33 (1999).
Aronov Alexander
Hale Michael Robin
Maltais Francois
Straub Judith
Tang Qing
Pearson Daniel A.
Rao Deepak
Vertex Pharmaceuticals Incorporated
LandOfFree
Heterocyclic inhibitors of ERK2 and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic inhibitors of ERK2 and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic inhibitors of ERK2 and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3942763